small molecule

SUPRAX

CEFIXIME

Loss of exclusivityDecember 2028latest FDA-listed patent expiry
CompanyLupinView the full company profile on CliffBio

Drug detail

Brand nameSUPRAX
Active ingredientCEFIXIME
Strength500MG/5ML
Dosage formFOR SUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2013
Marketing statusRX

Listed patents

PatentExpiresType
9233112December 2028product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

SUPRAX patent cliff — loss of exclusivity December 2028 | CliffBio